The High Authority for Health in France (HAS) on Monday, November 8 advised against the use of the Moderna vaccine for those under 30, based in particular on a study according to which it slightly increases the risk of myocarditis and pericarditis for this population.
Read also Covid-19: Moderna will set up a first vaccine plant in Africa
Led by the Epi-Phare structure, which associates the Health Insurance (Cnam) and the Medicines Agency (ANSM), a large study published on Monday focused on people aged 12 to 50 years hospitalized in France for myocarditis or pericarditis between May 15 and August 31, or 919 cases of myocarditis and 917 cases of pericarditis.
Myocarditis and pericarditis are inflammations of the heart.
The first affects the myocardium, the main heart muscle, and the second the pericardium, the membrane that surrounds the heart.
As had been shown by pharmacovigilance reports, the results of the French study confirm that Pfizer and especially Moderna vaccines increase the risk of these diseases occurring within 7 days after vaccination, and more often in men less 30 years old.
The preferred dose of Pfizer
In view of these results, the HAS "
recommends, for the population under the age of 30 and when it is available, the use of the Pfizer vaccine whether it is a primary vaccination or a booster
". Conversely, she recommends that the Moderna vaccine, "
whose vaccine efficacy seems slightly better, can be used as a primary vaccination course and for the administration of a booster dose in half-dose in subjects over the age of 30. years
On October 15, the French National Authority for Health recommended using exclusively the Pfizer / BioNtech vaccine for booster doses. "
When we weigh the effectiveness of vaccines against severe forms of Covid-19 (estimated at around 90%) and the existing but infrequent risks of myocarditis and pericarditis, which progress favorably, the benefit-risk ratio of vaccines is not called into question
”, assured Monday to AFP Mahmoud Zureik, director of the structure Epi-Phare.
The HAS for its part reiterates the imperative to vaccinate as widely as possible.
The epidemic is currently marking a resumption of which it is difficult to predict the evolution, but the winter period which is starting together with the foreseeable drop in the effectiveness of vaccines in people vaccinated before the summer once again reminds us of the importance to obtain the best possible vaccination coverage for the entire population and in particular for people most likely to have a serious form of Covid-19,
”insists the High Authority for Health.
To read also Stéphane Bancel: "It was impossible to imagine the future of Moderna without a factory in Africa"
It also considers it necessary to "
maintain a high level of protection by administering a booster dose in the most fragile populations and the most exposed to the virus
A health defense council is scheduled for Tuesday morning in Paris.
In the evening, President Emmanuel Macron will address the French again to discuss the health crisis in particular.